BIIB Oct 2024 255.000 call

OPR - OPR Delayed Price. Currency in USD

Add to watchlist

7.42

0.00

(0.00%)

At close: 11:59AM EDT

Loading interactive chart...

Investor's Business Daily
Is Eli Lilly Stock A Buy After FDA Advisors Back Its Alzheimer's Drug?
Is Eli Lilly stock a buy after a panel of advisors to the FDA unanimously backed its Alzheimer's drug? Is LLY stock a buy right now?
Zacks
Ionis (IONS) Expands Licensing Deal With Otsuka for HAE Drug
Ionis (IONS) out-licenses the rights for its HAE drug to Otsuka in the Asia-Pacific region. The companies signed a similar deal last year granting Otsuka rights to market the drug in Europe.
Zacks
Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab (Revised)
If Eli Lilly's (LLY) donanemab is approved by the FDA, it will become the second drug approved by the FDA to reduce the clinical decline associated with Alzheimer's disease.